Patient Input Needed for Review of New Migraine Medicines by May 8
The Institute for Clinical and Economic Review (ICER) is assessing the new class of CGRP inhibitor medicines for migraine prevention. Insurance companies will use ICER’s final report (as well as other information) when determining if they will cover these medicines, what tier the medicines will be in on the plans’ formularies, and what types of prior authorization or step therapy will be required.
Despite the migraine community’s petitioning, ICER does not have a migraine patient or a headache specialist on the voting panel that will be making their final decision. Without a personal or specialist voice representing migraine on the panel, it is vital that ICER hears from migraine patients.
Almost 200 migraine patients shared their stories with ICER during the first Public Comment period in November 2017. These submissions have helped to inform the process thus far, but patients need to submit their stories again for the panel. The American Migraine Foundation encourages patients to share their stories.
Official AMF Partners Headache and Migraine Policy Forum and Golden Graine, collaborated with CHAMP to produce an Updated Patient Guide. The guide provides all the information patients need on what to cover and how to submit your migraine story. The deadline for submissions is May 8, 2018.
Original Content Source